Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,626external-prioritypatent/US5695768A/en
Priority claimed from US08/477,497external-prioritypatent/US5866132A/en
Priority claimed from CA002153730Aexternal-prioritypatent/CA2153730A1/en
Priority claimed from CA002153733Aexternal-prioritypatent/CA2153733A1/en
Application filed by Alberta Res CouncilfiledCriticalAlberta Res Council
Priority claimed from NZ309713Aexternal-prioritypatent/NZ309713A/en
Publication of NZ337730ApublicationCriticalpatent/NZ337730A/en
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Saccharide Compounds
(AREA)
Abstract
A conjugate having at least one oligosaccharide hapten having a multiple of repeat subunits and retaining at least one immunogenic epitope and a carrier which elicits a thymus dependent immune response in a subject is used in the manufacture of a medicament for providing an immune response against bacterial or viral pathogens in a mammal in need of such treatment. The oligosaccharide can from S. pneumoniae serotype 8 and the mammal can be a neonate.
NZ337730A1995-06-071996-06-06use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering
NZ337730A
(en)
Induction of a cytotoxic T-lymphocytic answer The invention relates to the medicine, particularly to the immunology and can be used for treatment of bacterial and parasitic infections, tumors and other diseases. The summary of the invention consists in the induction of a cytotoxic T-lymphocytic answer to human and animals by means of a composition consisting of an antigene and an antigenic formulati
Combination of diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin and capsular polysaccharide of haemophilus influenzae type b (InfanrixHib)